Niki BioSolutions, Inc. (NIKI) stock
Close on Nov 17, 2026Market cap $12.22MP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Dec 31, 2025
Valuation
- Market cap
- $12.22M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 0.53
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Net income
- -$1.36M
- EPS, diluted
- -$0.19
- Book value per share
- $2.89
- Diluted shares
- 8M
Trading
- Previous close
- $1.70
- Open
- $1.71
- Day's range
- $1.50 – $1.71
- Volume
- 6,381
- Average volume (20 days)
- 20,672
- 52-week range
- $1.42 – $17.20
- RSI (14 days)
- 29.1
- Volatility (1 year)
- 100.5%
- Relative volume
- 0.05×
Market cap history
Month-end market cap since 2019, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 17, 2026. The S&P 500 is measured by the SPY fund.
| Period | NIKI | S&P 500 | Difference | NIKI per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -26.1% | -4.0% | −22.1 pts | ||
| 3 months | -81.8% | -5.0% | −76.9 pts | ||
| Year to date | -85.8% | +8.2% | −94.1 pts | ||
| 1 year | -88.9% | +11.2% | −100.1 pts | ||
| 3 years | -91.1% | +68.5% | −159.5 pts | -55.3% | +19.0% |
| 5 years | -99.3% | +67.3% | −166.6 pts | -62.9% | +10.8% |
Nine years at a glance
Fiscal years 2017 to 2025, USD
Revenue
Gross profit
Net income
EPS, diluted
Free cash flow
Press releases
Releases Niki BioSolutions filed with the SEC as exhibits to Form 8-K or 6-K
- News
- News
- News
- 6-K
- 6-K
- 6-K
About Niki BioSolutions
Measuring & Controlling Devices, NEC
Aptorum Group Limited is a clinical-stage biopharmaceutical enterprise focused on researching, developing, and commercializing novel therapeutic drug candidates and healthcare solutions. Its primary development pipeline centers on preclinical and clinical drug assets, including its lead projects ALS-4 and SACT-1, with SACT-1 targeted as a pediatric formulation for neuroblastoma. In addition to pharmaceutical drug candidates, the organization previously engaged in healthcare service operations through an outpatient medical clinic known as Talem Medical, serving individual clinical patients via employed physicians.
Company profile, executives and historyNiki BioSolutions stock: common questions
What is Niki BioSolutions's stock price?
NIKI closed at $1.50 on Nov 17, 2026, down 11.76% on the day. Over the past 52 weeks it traded between $1.42 and $17.20.
What is Niki BioSolutions's market cap?
Niki BioSolutions was worth $12.22M at the close on Nov 17, 2026: the share price times the diluted shares outstanding.
What is NIKI's P/E ratio?
Niki BioSolutions lost money over the twelve months to Dec 31, 2025 (diluted EPS -$0.19), so it has no meaningful P/E ratio.
Does Niki BioSolutions pay a dividend?
No. Niki BioSolutions has not paid a cash dividend over the last twelve months.
How has NIKI stock performed over the past year?
Including dividends, NIKI returned -88.9% over the past year, against +11.2% for the S&P 500.
How many NIKI shares are sold short?
0M shares were sold short at the latest FINRA report, 0.03% of the float, or 1.0 days of average trading volume.
Who are Niki BioSolutions's competitors?
Companies most similar to Niki BioSolutions by business, industry and size include QSI, TMO, MIR, HBIO, EYPT.
See a number that looks wrong?